Analysis-Hims & Hers GLP-1 pill gambit backfires, accelerating crackdown on drug compounders [Yahoo! Finance Canada]
Hims & Hers Health, Inc. Class A (HIMS)
Company Research
Source: Yahoo! Finance Canada
NEW YORK, Feb 19 (Reuters) - Online telehealth company Hims & Hers Health, seeking growth drivers as its original sexual-health franchises matured, may have overstepped with a risky launch of weight-loss pills that drew swift blowback from Danish drugmaker Novo Nordisk and U.S. regulators. Even as Novo and U.S. rival Eli Lilly had ?moved to aggressively cut prices on their GLP-1 weight-loss drugs, Hims announced plans to offer a compounded oral semaglutide pill for $49 - a version of Novo Nordisk's new Wegovy ?pill launched in January. Two days later, Hims retreated after U.S. FDA Commissioner Marty Makary warned the offering and similar drugs were "illegal copycats." Novo followed up by suing the telehealth company for infringing patents on its injectable weight-loss offerings. The oral GLP-1 could ?have opened a new market for Hims with patients who prefer pills to injections, analysts said. Now it's not clear where the company will look for long-term growth prospects. "T
Show less
Read more
Impact Snapshot
Event Time:
HIMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HIMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HIMS alerts
High impacting Hims & Hers Health, Inc. Class A news events
Weekly update
A roundup of the hottest topics
HIMS
News
- 4 stocks to watch on Thursday: HIMS, DPZ, WMT, PSX [Seeking Alpha]Seeking Alpha
- Hims & Hers Announces Agreement to Acquire Eucalyptus, Accelerating Its Vision to Become the Leading Global Consumer Health PlatformBusiness Wire
- HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law FirmGlobeNewswire
- Hims & Hers Health (HIMS) Is Down 29.2% After Semaglutide Lawsuit And DOJ Referral - Has The Bull Case Changed? [Yahoo! Finance]Yahoo! Finance
- Hedge funds bet big against Hims & Hers Health before Wegovy showdown, Hazeltree data shows [Yahoo! Finance Canada]Yahoo! Finance Canada
HIMS
Earnings
- 11/3/25 - Miss
HIMS
Sec Filings
- 2/19/26 - Form 8-K
- 2/13/26 - Form SCHEDULE
- 2/4/26 - Form 4
- HIMS's page on the SEC website